Impact of the WHO Recommended Vitamin A Supplementation at Immunisation

Status Terminated

Clinical Trial Summary

High-dose vitamin A to children above 6 months of age reduces all-cause mortality by 23-30%. The WHO recommends vitamin A supplementation (VAS) with the first vaccine after 6 months of age. However, the effect of providing VAS with vaccines has never been investigated. We have hypothesised that the effect of VAS depends on the immune stimulus at the time of supplementation. Hence, the effect might vary depending on which type of vaccine it is given with. In particular, we hypothesised that VAS might be beneficial when given with measles vaccine but not when given with DTP vaccine. Normally the first vaccine after 6 months of age would be a measles vaccine, but many children come late for their DTP vaccinations and receive DTP alone or together with measles vaccine. Hence, it is important to study whether the effect of VAS is the same irrespective of the vaccine(s) administered at the same time.

Guinea-Bissau has not yet implemented the WHO vitamin A policy of providing VAS with vaccines, but plans to do so within the next years. Together with the Ministry of Health in Guinea-Bissau, the Bandim Health Project (BHP) in Guinea-Bissau will investigate the effect on mortality and morbidity of implementing the WHO vitamin A policy in Guinea-Bissau. This will be done in a large randomised trial.

BHP has a demographic surveillance system (DSS) which has followed a population of now more than 150,000 individuals for almost 30 years. Children will be randomised to receive VAS or placebo with their first vaccine after 6 months of age, and will be followed through the DSS to assess mortality and morbidity. Based on previous observations, the effects of VAS might differ according to sex and season. The interaction between VAS, sex, and season will also be studied in the present trial. By identifying situations where VAS may be beneficial, ineffective, or even harmful the study may contribute importantly to optimising the VAS policy for low-income countries.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00514891
Study type	Interventional
Source	Bandim Health Project
Contact
Status	Terminated
Phase	Phase 4
Start date	August 2007
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04507867` - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III	N/A
Completed	`NCT04092465` - Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)
Completed	`NCT03296423` - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly	Phase 4
Not yet recruiting	`NCT04900610` - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis	N/A
Completed	`NCT04149873` - Effectness of Treatment With Mechanical Insufflation-Exsufflation	N/A
Completed	`NCT05905042` - Follow-up of Recovery Condition in Survivors of Acute Respiratory Distress Syndrome
Completed	`NCT00527774` - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients	N/A
Completed	`NCT00518856` - Lufwanyama Neonatal Survival Project	N/A
Completed	`NCT06408636` - Prognostic Role of LA Strain in Acute Myocardial Infarction
Completed	`NCT06051526` - The African Critical Illness Outcomes Study
Recruiting	`NCT05055089` - Short- and Medium-term Results of New Generation Aortic
Active, not recruiting	`NCT04132492` - AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients
Completed	`NCT03885206` - Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital	N/A
Completed	`NCT05573659` - Capillary Refill Time Calculated With a Video-assisted Method Has a Better Reproducibility Than Visual Method in Critically Ill Patients	N/A
Withdrawn	`NCT03245658` - The Effect of Cannabis in Pancreatic Cancer	Phase 2
Recruiting	`NCT04094428` - Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Completed	`NCT01631799` - Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia	N/A
Completed	`NCT00244673` - Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination	Phase 4
Completed	`NCT03378843` - Spermidine Intake and All-cause Mortality	N/A
Recruiting	`NCT04424511` - Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms